

Special Lecture 1 : The finding, development and progress of potassium channel openers

著者	柳澤 輝行
URL	http://hdl.handle.net/10097/57060



The 87th Annual Meeting of The
Japanese Pharmacological Society
Sendai, 20140319, 10:45-11:45

Special Lecture 1

The finding, development and progress of
potassium channel openers.



Teruyuki YANAGISAWA, MD, PhD
Dept. Mol. Pharmacol.,
Tohoku Univ. Sch. Grad. Med.



☒ The author has no conflict of interest to disclose with respect to this presentation.

The development of nicorandil (SG-75)


The development of nicorandil (SG-75) was started under the concept “**a nitrate-like antianginal drug without hypotensive side effect**”. During the studies to explore the mechanism of action of nicorandil, it has been revealed that nicorandil opens potassium (K^+) channel and that ATP-sensitive K^+ channels (K_{ATP}) are the target molecules, which are also opened by other K^+ channel openers (KCO) as antihypertensives. Although the clinical results related with pure KCOs for hypertension have been failed, nicorandil which is a hybrid of nitrate and KCO has been successful as a drug for angina pectoris, acute myocardial infarction and acute heart failure. We have also suggested that nicorandil will be effective in managing pulmonary arterial hypertension. The KCOs targeting other than K_{ATP} are expected to be novel therapeutic agents to control pain or epilepsy, including many pathological situations.

K⁺ channel openers (K_{ATP}COs)


- Historical points of view
- Why they are **not** successful for the antihypertensive agents?
- Vasospastic angina
- Hyperpolarization-relaxation coupling
- Progress of new types KCOs

K⁺ channel openers


Pyridine: **nicorandil**
KRN2391



Benzothiadiazine:
diazoxide



Benzopyran:
Cromakalim




Hyperglycemia
(side effect)

Insulin secretion ↓
K_{ATP} open in β cell

cf. ischemic preconditioning;
pharmacological

Pyrimidine:
minoxidil, LP 805



trichogen

Hypertrichosis
as a side effect

The development of nicorandil (SG-75)

- Blood-perfused cardiac preparations in Tohoku University
- The serendipity to find K⁺ opening activity



Hashimoto, Koroku



Taira, Norio



東北大学



創薬の狩人

新薬創製への道

境 一成 著



新薬の芽の段階から一貫して
研究開発に携わり、
国際開発、製品育成研究を
体験した研究者が綴る初めての
“創薬ハンターの物語”

共立出版

Dr. Sakai, K
(Born in Ishinomaki)
2000年11月

ISBN4-320-05499-7

C3045 ¥3000E

PNE
モノグラフ

定価(本体3,000円+税)

創薬の狩人 新薬創製への道

境 一成 著

共立出版株式会社

- 第1章 創薬の狩人(ハンター)の登場
- 第2章 創薬に着手するには
- 第3章 新薬創製を妨げようとする障壁をいかに克服するか
- 第4章 逆転の発想
- 第5章 わが国の代表的な創薬の具体例
- 第6章 ニコランジルの創製
- 第7章 薬はどのようにして世に出るか
- 第8章 治療体系
- 第9章 人間の身体の仕組み
- 第10章 創薬ハンターとしての心がまえ

The Development of nicorandil

の狩人

新薬創製への道


境一成 著



- 第1章 創薬の狩人(ハンター)の登場
- 第2章 創薬に着手するには
- 第3章 新薬創製を妨げようとする障壁をいかに克服するか
- 第4章 逆転の発想
- 第5章 わが国の代表的な創薬の具体例
- 第6章 ニコランジルの創製
- 第7章 薬はどのようにして世に出るか
- 第8章 治療体系
- 第9章 人間の身体の仕組み
- 第10章 創薬ハンターとしての心がまえ

a nitrate-like antianginal drug without hypotensive side effect

Increase in coronary flow by nicorandil



Modified from Taira N et al. Clin Exp Pharmacol Physiol 1979; 6:301-316.

i. v.: intravenous injection

Nicorandil (SG-75): coronary resistance↓

Intraduodenal administration of nicorandil (3mg/kg)

≡ intravenous injection (0.3mg/kg)

	Basal value		Value after SG-75*
Coronary sinus outflow (ml/min)	21.6	(3.0)	40.4 (5.0)†
Mean blood pressure (mmHg)	89	(6)	53 (8)†
Coronary resistance (mmHg min/ml)	4.5	(0.8)	1.5 (0.4)†
Coronary a.v. O ₂ difference (vol.%)	12.1	(0.04)	6.9 (0.9)†
Myocardial O ₂ consumption (ml/min per 100 g)	4.1	(0.7)	4.4 (0.8)
Heart rate (beats/min)	180	(15)	170 (3)†
AV Conduction time (ms)	100	(2)	98 (1)

† : P<0.05, SEM in parentheses, n=5.

a.v.: arterio-venous; AV: atrioventricular

Taira N, Satoh K, Yanagisawa T et al. Clin Exp Pharmacol Physiol 1979;6:301-16.

Nicorandil (SG-75): coronary resistance ↓

Coronary resistance 4.5 → 1.5

Change In the systemic resistance: —40%

Coronary sinus outflow (ml/min)	21.6 (3.0)	40.4 (5.0)†
Mean blood pressure (mmHg)	89 (6)	53 (8)†
Coronary resistance (mmHg min/ml)	4.5 (0.8)	1.5 (0.4)†
Coronary a.v. O ₂ difference (vol.%)	12.1 (0.04)	6.9 (0.9)†
Myocardial O ₂ consumption (ml/min per 100 g)	4.1 (0.7)	4.4 (0.8)
Heart rate (beats/min)	180 (15)	170 (3)†
AV Conduction time (ms)	100 (2)	98 (1)

† : P<0.05, SEM in parentheses, n=5.

a.v.: arterio-venous; AV: atrioventricular



Taira N, Satoh K, Yanagisawa T et al. Clin Exp Pharmacol Physiol 1979;6:301-16.

Distribution of cardiac output & O₂ consumption in organs at rest



Organs	Blood flow (mL/min)			O ₂ consumption	
	(/100g)	(Whole)	(%)	(mL/min)	(%)
Brain	57	750	15	46	20
Heart	70	200	4	27	11
Liver	95	1,350	27	33	14
Kidney	420	1,200	24	16	7
Sk. muscle	3	850	16	70	30
Skin	7	350	7	5	2
Others		400	7	36	16
Total		5,100	100	233	100

In heart, the tissue O₂ partition pressure is low, thus the organ is under relatively hypoxic condition. K_{ATP} channels are seemed to be easily opened in heart.

Isolated blood-perfused cardiac preparations



Increase in coronary blood flow, Very little effect on sinoatrial (SA) rate




SG-75

Nicorandil

Injection, i. a.


Constant perfusion pressure

Conduction system




AV node; PSA: posterior septal artery←circumflexus artery
Ventricle; ASA: anterior septal artery←left coronary artery


Nifedipine vs. nicorandil on AV conduction time



N-Sch. Arch. Pharmacol. 1975;290:107-12.



No effect on AV conduction, furthermore



CIRCUMSTANTIAL EVIDENCE FOR INCREASED POTASSIUM CONDUCTANCE OF MEMBRANE OF CARDIAC MUSCLE BY 2-NICOTINAMIDOETHYL NITRATE (SG-75)

Teruyuki YANAGISAWA, Keisuke SATOH and Norio TAIRA

*Department of Pharmacology, Tohoku University School of Medicine,
Sendai 980, Japan*

Accepted April 19, 1979

Abstract—The mechanism of action of 2-nicotinamidoethyl nitrate (SG-75), was investigated by the use of arterially blood-perfused papillary muscle preparations of the dog. All drugs were administered intra-arterially. SG-75 shortened the effective refractory period (ERP) and decreased the rate of automaticity and developed tension of the papillary muscle, whereas verapamil failed to change the ERP despite a decrease in the developed tension. SG-75 in extremely high doses induced ventricular fibrillation. Methacholine produced decreases in the rate of automaticity and developed tension, and the actions were abolished by atropine. The SG-75-induced decreases in two parameters were not modified by atropine. These results indicate that the cardiac action of SG-75 differs from that of calcium-antagonistic vasodilators and it is suggested that the basic mechanism of action of SG-75 involves an increase in potassium conductance in the membrane of cardiac muscle, without mediation through muscarinic receptors.

Nicorandil suppresses Purkinje rate





FIG. 2. Effects of SG-75 injected into the anterior septal artery on the developed tension and on the rate of automaticity of a canine blood-perfused papillary muscle.

Nicorandil 1mg, i.a.

Extra.
potential




Fc



Blood-
perfused
papillary
muscle

Force of contraction

Extra. potential



Arterial blood

Nicorandil


Acute ischemia causes a so-called
current of injury????

The concept of K_{ATP} channel opening
in ischemic/hypoxic cells.


The effect of on APD of cardiac muscle.
(Ischemia-induced arrhythmia)
(Intra-arterial nicorandil-induced V.F.)

Acute ischemia causes a current of injury

Effort angina
predominant
subendocardial
ischemia




Vasospastic angina, acute myocardial infarction
ischemia involving the outer
ventricular layer (transmural
or epicardial injury)




Lead V4 **at rest** (*top*) and after 4.5 min of **exercise** (*bottom*).



There is 0.3 mV of **horizontal ST-segment depression**, indicating a positive test for ischemia.





Acute ischemia causes ST changes





Ischemic arrhythmias in the light of K_{ATP}

Reentry \rightarrow VT, VF



SG-75-induced VT & VF in experiments with blood-perfused canine preparations



We have given clinicians the caution of the risk of **intracoronary administration** of nicorandil.

Fortunately, there has been no report related accidents

Nicorandil as a Hybrid Between Nitrates and Potassium Channel Activators


Norio Taira, MD

(Am J Cardiol 1989;63:18J-24J)

• Cromakalim and pinacidil, nonnitrate KCO, have essentially the same cardiovascular profile as nicorandil in isolated, blood-perfused canine heart preparations.

- 1) The property of nicorandil as a resistive vessel dilator highly selective for vasculature originates in its mechanism of action as a K-channel activator.
- 2) The non-unanimous effect of nicorandil on venous return is a result of the opposing actions as a capacitive (action as a nitrate) and a resistive vessel dilator.
- 3) Nicorandil, with its hybrid nature, is advantageous over specific K-channel activators and classic nitrates in therapeutic implications.


Selectivity spectra for coronary blood flow vs. cardiac variables



Canine atrial muscle comparison with ACh

SG-75


Untreated




Canine atrial muscle comparison with ACh

SG-75

Untreated




Atropine 3×10^{-7} mol/l




MeCh


Untreated




Atropine 3×10^{-7} mol/l



SG-75 increases P_K




Effect of SG-75 on membrane potentials of a spontaneously firing canine Purkinje fiber




Slow response in 27 mM K⁺


a) SG-75



b) MeCh



c) Verapamil



Hyperpolarization

Shorten APD

【Conclusion-1】

Findings in blood-perfused cardiac prep.

- **SG-75 increases coronary blood flow.**
- No effect on AV conduction
- Induction of ventricular fibrillation in high dose
- Shorten QT interval
- Shorten APD of ventricular muscle

The mechanism is not Ca^{2+} channel blockade.

K^{+} channel opening.

K⁺ channel openers (K_{ATP}COs)

- Historical points of view
- Why they are **not** successful for the antihypertensive agents?
- Vasospastic angina
- Hyperpolarization-relaxation coupling
- Progress of new types KCOs

As a model of vasospastic angina

**Abolition of Spontaneous Rhythmic
Contractions of Isolated Monkey
Coronary Arteries by Diltiazem,
Nifedipine, Verapamil and Nicorandil
but Not by Nitroglycerin**

KUNIAKI ISHII, TERUYUKI YANAGISAWA, KEISUKE SATOH
and NORIO TAIRA

*Department of Pharmacology, Tohoku University School of
Medicine, Sendai 980*


Treatment of **vasospastic angina**

Rest


Attack 1min

Control

V₃




BP 130/82




162/78

Diltiazem

V₃




BP 114/70




158/58

Propranolol

V₃



BP 122/84



100/78





Fig. 1. Spontaneous rhythmic contractions of a coronary artery ring of the left circumflex coronary artery of a rhesus monkey and effects of vasodilators thereon.

Hypertension, spasm, agonists

depolarization


rested

hyperpolarization




Dissociation of $[Ca^{2+}]_i$ & Force of contraction


KCl (90 mM) contraction




Repolarization vs. Inhibition of Ca influx




Repolarization vs. Inhibition of Ca influx




[Ca²⁺]_i-Fc relation; **V_m**



Repolarization & Ca sensitivity



RhoK distribution



Cytosolic distribution of activated RhoA in isolated myocytes and effect of the Rho-associated kinase (ROCK) inhibitor Y27632 on 70K-induced contraction in rat basilar artery. Confocal immunofluorescent images of RhoA distribution (RhoA, green; cell nucleus, red) in a single basilar smooth muscle cell at rest (A) and after stimulation with 70K (B). Scale bars=7 μm.

Fernandez-Tenorio et al.: Circ Res 2011;108:1348-57.

Agonist contraction & KCl depolarization

Force (mN)



Ratio (F340/F380)



ET-1




90 mM KCl




0 mM CaCl_2



Relationship between $[Ca^{2+}]_i$ and force of contraction induced by serotonin ($10^{-6.5}$ M) in the absence (○) and presence of levcromakalim ($10^{-5.5}$ M, ●) or nicardipine (■).




K⁺ channel opener inhibits IP₃ generation & Ca²⁺ release from SR by a thromboxane A₂ analogue. **Hyperpolarization-relaxation coupling**




Naunyn-Schmied. Arch. Pharmacol. 1992;346:691-700.
Biochem. Biophys. Res. Commun. 1992;187:1517-22.

Activation of phospholipase C by the agonist U46619 is inhibited by cromakalim-induced hyperpolarization in porcine coronary artery. (in the absence of $[Ca^{2+}]_o$)



Molecular signal mechanisms of **relaxation** of vascular smooth muscle via **Hyperpolarization**



Hyperpolarization decreases Ca sensitivity

KCO

Nicorandil

Nitroglycerin


EDHF

K_{ATP}

K_{Ca}

K_{ir}

as NK hybrid




Nicorandil, Nitroglycerin




NO → cGMP → G kinase

In the presence of nitroglycerin, Dissociation of $[Ca^{2+}]_i$ & Fc





Pathogenic mechanisms in coronary artery spasm.



【Conclusion-2】

Coronary artery spasm mechanisms.

Ca²⁺ sensitivity in vasc. sm. m. is increased or decreased by depolarization or hyperpolarization, respectively.

The concept of hyperpolarization-relaxation coupling *via*. KCO or EDHF is very important, since we have precisely known the molecular mechanisms of vasospasm.




K⁺ channel openers (K_{ATP}COs)

- Historical points of view
- Why they are **not** successful for the antihypertensive agents?
- Vasospastic angina
- Hyperpolarization-relaxation coupling
- Progress of new types KCOs

【Appendix】

The future of K_{ATP} COs & other type of KCOs

- Organ perfusion preservation of organ transplant
- Pulmonary arterial hypertension; *Sahara M et al. PLoS One. 2012;7(3):e33367. doi: 10.1371/journal.pone.0033367.*
- Advanced diabetic nephropathy; *Tanabe K et al. Am J Physiol Renal Physiol. 2012;302:F1151-60.*
- Peripheral vascular diseases




BK_{Ca} , IK_{Ca} ~ 100 pS, ~ 60 pS


K_{ATP} ~ 100 pS, ~ 10 pS

K_v ~ 10 pS


Other types KCOs




Maxikdiol



一般式 (I) 今泉祐治, 大和田智彦
特許第3973561号 カリウムチャネル開口薬





MS-12-709



NS-1619

Anticonvulsant, Analgesic

- Ezogabine (Retigabine): KCNQ/Kv7 opener, anticonvulsant.
- Flupirtine: the same mechanism , non-opioid analgesic, muscle relaxant and anticonvulsant.



Thank you for your attention!

魯迅の階段教室



20130412 教室の外で